<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39360169</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2341-4545</ISSN><JournalIssue CitedMedium="Print"><Volume>31</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>GE Portuguese journal of gastroenterology</Title><ISOAbbreviation>GE Port J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses.</ArticleTitle><Pagination><StartPage>325</StartPage><EndPage>337</EndPage><MedlinePgn>325-337</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000534740</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Three years after the beginning of the SARS-CoV-2 pandemic, the safety and efficacy of COVID-19 vaccination in liver cirrhosis (LC) patients remain controversial. We aimed to study the safety, immunological, and clinical responses of LC patients to COVID-19 vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Prospective multicentric study in adults with LC eligible for COVID-19 vaccination, without prior known infection. Patients were followed up until the timing of a booster dose, SARS-CoV-2 infection, or death. Spike-protein immunoglobulin G antibody titers for SARS-CoV-2 at 2 weeks, 3 months, and 6 months postvaccination were assessed. Antibody titers &lt;33.8 binding antibody units (BAU)/mL were considered seronegative and &lt;200 BAU/mL suboptimal. Postvaccination infection and its severity were registered.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We included 124 LC patients, 81% males, mean aged 61 ± 10 years, with a mean follow-up of 221 ± 26 days. Alcohol was the most common (61%) cause of cirrhosis, and 7% were under immunosuppressants for autoimmune hepatitis; 69% had portal hypertension, 42% had a previous decompensation, and 21% had a Child-Pugh-Turcotte score of B/C. The type of vaccine administrated was BNT162b2 (<i>n</i> = 59, 48%), ChAdOx1nCoV-19 (<i>n</i> = 45, 36%), mRNA-1273 (<i>n</i> = 14, 11%), and Ad26.COV2.S (<i>n</i> = 6, 5%). Eighteen percent of the patients reported adverse events after vaccination, none serious. Median [Q1; Q3] antibody titers were 1,185 [280; 2,080] BAU/mL at 2 weeks, 301 [72; 1,175] BAU/mL at 3 months, and 192 [49; 656] BAU/mL at 6 months. There were seronegative and suboptimal antibody responses in 8% and 23% of the patients at 2 weeks, 16% and 38% at 3 months, and 22% and 48% at 6 months. Older age and adenovirus vector vaccines were the only factors associated with seronegative and suboptimal responses at 2 weeks and 3 months (<i>p</i> &lt; 0.05) in a multivariable logistic regression analysis. Eleven patients (9%) were infected with SARS-CoV-2 during follow-up (3.8-6.6 months postvaccination), all with mild disease. There were no differences regarding the type of vaccine, and 73% had antibody titers &gt;200 BAU/mL at 3 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">COVID-19 vaccines in patients with LC were safe, without serious adverse events. The humoral and clinical responses were similar to the reported for the general population. Humoral response was adversely impacted by older age and adenovirus vector vaccines and unrelated to the liver disease severity.</AbstractText><CopyrightInformation>© 2023 The Author(s).Published by S. Karger AG, Basel.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canha</LastName><ForeName>Inês</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Mário Jorge</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Maria Azevedo</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar de Leiria, Leiria, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarmento Costa</LastName><ForeName>Mara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saraiva</LastName><ForeName>Rita Ornelas</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruge</LastName><ForeName>André</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar de Leiria, Leiria, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Mariana Verdelho</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Félix</LastName><ForeName>Catarina Sousa</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morão</LastName><ForeName>Bárbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Hospital Beatriz Ângelo, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueiredo</LastName><ForeName>Pedro Narra</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendes</LastName><ForeName>Milena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leal</LastName><ForeName>Carina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar de Leiria, Leiria, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calinas</LastName><ForeName>Filipe</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Gastroenterology Department, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>GE Port J Gastroenterol</MedlineTA><NlmUniqueID>101685861</NlmUniqueID><ISSNLinking>2387-1954</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="INTRODUÇÃO" NlmCategory="UNASSIGNED">Três anos após o início da pandemia SARS-CoV-2, a segurança e eficácia da vacinação COVID-19 em doentes com cirrose hepática (CH) permanecem controversas. Pretendemos avaliar a segurança, respostas imunológica e clínica de doentes com CH às vacinas contra a COVID-19.</AbstractText><AbstractText Label="MÉTODOS" NlmCategory="UNASSIGNED">Estudo prospetivo multicêntrico em adultos com CH elegíveis para vacinação contra a COVID-19, sem infeção prévia conhecida. Os doentes foram acompanhados até ao momento da dose de reforço, infeção SARS-CoV-2 ou falecimento. Avaliámos os títulos de anticorpos IgG da proteína-<i>Spike</i> SARS-CoV-2 às 2 semanas, 3 meses e 6 meses. Títulos de anticorpos &lt;33.8 BAU/mL foram considerados seronegativos e &lt;200 BAU/mL subótimos. A ocorrência de infeção pós-vacinação e respetiva gravidade foram registadas.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">Incluímos 124 doentes com CH, 81% homens, com idade média de 61 ± 10 anos e um seguimento médio de 221 ± 26 dias. A causa mais prevalente de cirrose foi o álcool (61%) e 7% dos doentes faziam terapêutica imunossupressora por hepatite autoimune. Existiam sinais de hipertensão portal em 69%, descompensação prévia em 42% e classificação de <i>Child-Pugh-Turcotte</i> B/C em 21%. O tipo de vacina administrada foi: BNT162b2 (<i>n</i> = 59, 48%), ChAdOx1nCoV-19 (<i>n</i> = 45, 36%), mRNA-1273 (<i>n</i> = 14, 11%) e Ad26.COV2.S (<i>n</i> = 6, 5%). Foram reportados efeitos adversos pós-vacinação em 18% dos participantes, nenhum deles grave. Os títulos medianos [Q1; Q3] de anticorpos foram 1.185 [280; 2.080] BAU/mL às 2 semanas, 301 [72; 1.175] BAU/mL aos 3 meses e 192 [49; 656] BAU/mL aos 6 meses. Observámos respostas humorais seronegativas e subótimas em 8% e 23% dos doentes às 2 semanas, 16% e 38% aos 3 meses e 22% e 48% aos 6 meses. A idade avançada e vacinas de vetor de adenovírus foram os únicos fatores associados a respostas seronegativas e subótimas às 2 semanas e 3 meses (<i>p</i> &lt; 0.05) em análise de regressão logística multivariada. Onze doentes (9%) desenvolveram infeção SARS-CoV-2 durante o seguimento (3.8–6.6 meses pós vacinação), todos com doença ligeira. Não observámos diferenças relativamente ao tipo de vacina, apresentando 73% deles títulos de anticorpos &gt;200 BAU/mL aos 3 meses.</AbstractText><AbstractText Label="CONCLUSÕES" NlmCategory="UNASSIGNED">A vacinação contra a COVID-19 em doentes com CH foi segura, sem efeitos adversos graves. As respostas humoral e clínica foram semelhantes às reportadas na população geral. A resposta humoral foi afetada negativamente pela idade avançada e vacinas de vetor de adenovírus e não apresentou relação com a gravidade da doença hepática.</AbstractText><CopyrightInformation>© 2023 The Author(s).Published by S. Karger AG, Basel.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Liver cirrhosis</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>4</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39360169</ArticleId><ArticleId IdType="pmc">PMC11444661</ArticleId><ArticleId IdType="doi">10.1159/000534740</ArticleId><ArticleId IdType="pii">534740</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettini E, Locci M. SARS-CoV-2 mRNA vaccines: immunological mechanism and beyond. Vaccines. 2021;9(2):147–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7918810</ArticleId><ArticleId IdType="pubmed">33673048</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. . COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020;586(7830):594–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, Li J, Pan H, Wu Y, Zhu F. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther. 2021;6(1):48–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7851657</ArticleId><ArticleId IdType="pubmed">33531462</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. Semin Immunol. 2020;50:101422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7670910</ArticleId><ArticleId IdType="pubmed">33262067</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrotra DV, Janes HE, Fleming TR, Annunziato PW, Neuzil KM, Carpp LN, et al. . Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials. Ann Intern Med. 2021;174(2):221–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596738</ArticleId><ArticleId IdType="pubmed">33090877</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T, Webb GJ, Barritt AS, Ginès P, Lohse AW, Moon AM, et al. . SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. Lancet Gastroenterol Hepatol. 2021;6(3):156–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832019</ArticleId><ArticleId IdType="pubmed">33444545</ArticleId></ArticleIdList></Reference><Reference><Citation>
Janssen Science . Use of janssen COVID-19 vaccine in patients with hepatic impairment; 2023. Available from: https://www.janssenscience.com/products/janssen-covid-19-vaccine/medical-content/use-of-janssen-covid-19-vaccine-in-patients-with-hepatic-impairment [Accessed on 28 04 2023].</Citation></Reference><Reference><Citation>Fix OK, Blumberg EA, Chang K, Chu J, Chung RT, Goacher EK, et al. . American association for the study of liver diseases expert panel consensus statement: vaccines to prevent coronavirus disease 2019 infection in patients with liver disease. Hepatology. 2021;74(2):1049–64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014184</ArticleId><ArticleId IdType="pubmed">33577086</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74(4):944–51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7867401</ArticleId><ArticleId IdType="pubmed">33563499</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, et al. . Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper. J Hepatol. 2022;77(4):1161–97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9296253</ArticleId><ArticleId IdType="pubmed">35868584</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T, Moon AM, Cook JA, Abd-elsalam S, Aloman C, Armstrong MJ, et al. . Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74(3):567–77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536538</ArticleId><ArticleId IdType="pubmed">33035628</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj JS, Garcia-Tsao G, Biggins SW, Kamath PS, Wong F, McGeorge S, et al. . Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort. Gut. 2021;70(3):531–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371484</ArticleId><ArticleId IdType="pubmed">32660964</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung K, Mok C, Mao X, Zhang R, Hung I, Seto W, et al. . COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: a meta-analysis. Clin Mol Hepatol. 2022;28(4):890–911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9597217</ArticleId><ArticleId IdType="pubmed">36263669</ArticleId></ArticleIdList></Reference><Reference><Citation>Simão AL, Palma CS, Izquierdo-Sanchez L, Putignano A, Carvalho-Gomes A, Posch A, et al. . Cirrhosis is associated with lower serological responses to COVID-19 vaccines in patients with chronic liver disease. JHEP Rep. 2023;5(5):100697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9939238</ArticleId><ArticleId IdType="pubmed">36844943</ArticleId></ArticleIdList></Reference><Reference><Citation>Iavarone M, Tosetti G, Facchetti F, Topa M, Er JM, Hang SK, et al. . Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: a prospective single center study. Dig Liver Dis. 2023;55(2):160–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9575378</ArticleId><ArticleId IdType="pubmed">36266209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J, Digitale JC, Pletcher MJ, Lai JC; N3C Consortium . Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: a National COVID Cohort Collaborative study. Hepatology. 2023;77(3):834–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538384</ArticleId><ArticleId IdType="pubmed">36799617</ArticleId></ArticleIdList></Reference><Reference><Citation>John BV, Deng Y, Scheinberg A, Mahmud N, Taddei TH, Kaplan D, et al. . Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis. JAMA Intern Med. 2021;181(10):1306–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8278308</ArticleId><ArticleId IdType="pubmed">34254978</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahrs C, Harrison N. Vaccine response in the immunocompromised patient with focus on cellular immunity. Vaccines. 2022;10(6):882–3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9230619</ArticleId><ArticleId IdType="pubmed">35746489</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization . Living Guidance for clinical management of COVID-19: World Health Organization; 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 [Accessed on 08 09 2023].</Citation></Reference><Reference><Citation>Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–93.</Citation><ArticleIdList><ArticleId IdType="pubmed">32785213</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. . Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-rammerstorfer S, et al. . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445431</ArticleId><ArticleId IdType="pubmed">32702298</ArticleId></ArticleIdList></Reference><Reference><Citation>Widge A, Rouphael N, Jackson L, Anderson E, Roberts P, Makhene M, et al. . Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7727324</ArticleId><ArticleId IdType="pubmed">33270381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. . WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7987302</ArticleId><ArticleId IdType="pubmed">33770519</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafrir A, Amer J, Hakimian D, Milgrom Y, Massarwa M, Hazou W, et al. . Advanced liver fibrosis correlates with impaired efficacy of pfizer-BioNTech COVID-19 vaccine in medical employees. Hepatol Commun. 2022;6(6):1278–88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110948</ArticleId><ArticleId IdType="pubmed">35147300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekpanyapong S, Reddy KR. Infections in cirrhosis. Curr Treat Options Gastroenterol. 2019;17(2):254–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101776</ArticleId><ArticleId IdType="pubmed">30980335</ArticleId></ArticleIdList></Reference><Reference><Citation>Beran A, Mhanna A, Mhanna M, Hassouneh R, Abuhelwa Z, Mohamed MFH, et al. . Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients. Proc. 2023;36(2):151–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9980592</ArticleId><ArticleId IdType="pubmed">36876272</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. . Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):427–39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997788</ArticleId><ArticleId IdType="pubmed">33814753</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A, De A, Singh MP, Rathi S, Verma N, Premkumar M, et al. . Antibody response and safety of ChAdOx1-nCOV (covishield) in patients with cirrhosis: a cross-sectional, observational study. Dig Dis Sci. 2023;68(2):676–84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510448</ArticleId><ArticleId IdType="pubmed">36156752</ArticleId></ArticleIdList></Reference><Reference><Citation>Ai J, Wang J, Liu D, Xiang H, Guo Y, Lv J, et al. . Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases (CHESS-NMCID 2101). A Multicenter Study. 2022;7(20):1516–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686447</ArticleId><ArticleId IdType="pubmed">34942370</ArticleId></ArticleIdList></Reference><Reference><Citation>Willuweit K, Frey A, Passenberg M, Korth J, Saka N, Anastasiou OE, et al. . Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers. Vaccines. 2022;10(3):377–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8949848</ArticleId><ArticleId IdType="pubmed">35335009</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. . Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Dury S, Waern J, Waldenström J, Alavanja M, Saed HH, Törnell A, et al. . Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination. JHEP Rep. 2022;4(7):100496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9045869</ArticleId><ArticleId IdType="pubmed">35502229</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeli F, Spanevello A, Reboldi G, Visca D, Verdecchia P. SARS-CoV-2 vaccines: lights and shadows. Eur J Intern Med. 2021;88(4):1–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084611</ArticleId><ArticleId IdType="pubmed">33966930</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry J, Osman S, Wright J, Richard-Greenblatt M, Buchan SA, Sadarangani M, et al. . Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review. PLoS One. 2022;17(4):e0266852–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8993021</ArticleId><ArticleId IdType="pubmed">35395052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakasis AD, Bitzogli K, Mouziouras D, Pouliakis A, Roumpoutsou M, Goules AV, et al. . Antibody responses after SARS-CoV-2 vaccination in patients with liver diseases. Viruses. 2022;14(2):207–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8876976</ArticleId><ArticleId IdType="pubmed">35215801</ArticleId></ArticleIdList></Reference><Reference><Citation>Duengelhoef P, Hartl J, Rüther D, Steinmann S, Brehm TT, Weltzsch JP, et al. . SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. United Eur Gastroenterol J. 2022;10(3):319–29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9004241</ArticleId><ArticleId IdType="pubmed">35289983</ArticleId></ArticleIdList></Reference><Reference><Citation>Efe C, Taşçılar K, Gerussi A, Bolis F, Lammert C, Ebik B, et al. . SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis. J Autoimmun. 2022;132(10):102906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9448709</ArticleId><ArticleId IdType="pubmed">36088883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulkarni AV, Jaggaiahgari S, Iyengar S, Simhadri V, Gujjarlapudi D, Rugwani H, et al. . Poor immune response to coronavirus disease vaccines in decompensated cirrhosis patients and liver transplant recipients. Vaccine. 2022;40(48):6971–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9595300</ArticleId><ArticleId IdType="pubmed">36374707</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Zhang Q, Ai J, Liu D, Liu C, Xiang H, et al. . Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. 2022;16(3):691–701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995697</ArticleId><ArticleId IdType="pubmed">35403977</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier A, Yu J, McMahan K, Liu J, Chandrashekar A, Maron JS, et al. . Differential kinetics of immune responses elicited by covid-19 vaccines. N Engl J Med. 2021;385(21):2010–2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8531985</ArticleId><ArticleId IdType="pubmed">34648703</ArticleId></ArticleIdList></Reference><Reference><Citation>John BV, Sidney Barritt A, Moon A, Taddei TH, Kaplan DE, Dahman B, et al. . Effectiveness of COVID-19 viral vector Ad.26.COV2.S vaccine and comparison with mRNA vaccines in cirrhosis. Clin Gastroenterol Hepatol. 2022;20(10):2405–8.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212810</ArticleId><ArticleId IdType="pubmed">35716904</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>